Clinical trials: BMS-986504
Carcinoma, Non-Small-Cell Lung
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer…
- Trial name
- NCT06855771
- Testing
- BMS-986504, Izalontamab Brengitecan
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Glioblastoma WHO Grade IV
Clinical Trial of BMS-986504 in Recurrent GBM Patients
This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 12 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue…
- Trial name
- NCT06883747
- Testing
- BMS-986504
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nader Sanai
Advanced Cancer, Solid Tumor
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.
- Trial name
- NCT07382544
- Testing
- MRTX1719, Olaparib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Healthy Female Participants
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of [14C]Navlimetostat (BMS-986504) in healthy female participants
- Trial name
- NCT07777133
- Testing
- Navlimetostat, [14C]Navlimetostat
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
- Conditions
- Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT07532902
- Testing
- BMS-986504, Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Peripheral Nerve Sheath Tumors, MPNST
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available…
- Trial name
- NCT07549022
- Testing
- BMS-986504
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ankit Mangla, MD
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it…
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm
- Trial name
- NCT07594626
- Testing
- Biospecimen Collection, Computed Tomography, Pemetrexed
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Northwestern University
Phase 2 Study, BMS-986504
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
- Conditions
- Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer
- Trial name
- NCT07283705
- Testing
- BMS-986504, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.
- Trial name
- NCT07077434
- Testing
- BMS-986504
- Where
- 12 sites in China, Japan
- Volunteers
- 32 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Ductal Adenocarcinoma
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination…
- Trial name
- NCT07076121
- Testing
- Navlimetostat, Gemcitabine, Nab-paclitaxel
- Where
- 269 sites in United States, Argentina and 34 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors With Homozygous MTAP Deletion
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of [14C]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase…
- Trial name
- NCT06672523
- Testing
- BMS-986504, [14C]-BMS-986504
- Where
- 3 sites in Hungary, Spain
- Volunteers
- 8 people
- Sponsor
- Bristol-Myers Squibb
Mesothelioma
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
By incorporating a platform trial protocol design, SELECTmeso will spearhead a next-generation precision medicine trial platform in relapsed mesothelioma for the UK enabling early evaluation of hypothesis-driven targeted…
- Trial name
- SELECTmeso (NCT07602946)
- Testing
- BMS-986504
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Southampton
Healthy Female Adults
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants
- Trial name
- NCT07800897
- Testing
- Navlimetostat, Itraconazole, Rifampin
- Where
- Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab…
- Trial name
- MountainTAP-29 (NCT07063745)
- Testing
- BMS-986504, Pembrolizumab, Cisplatin
- Where
- 321 sites in United States, Argentina and 32 more
- Volunteers
- 590 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb